Colbeck Capital Supports World NF Awareness Day and the Children's Tumor Foundation
World NF Awareness Day takes place annually on May 17 during NF Awareness Month, a dedicated time to elevate the inspirational and remarkable stories of those living with NF, and the critical need for research to better their lives. Through dedicated events and partner initiatives around the world, the Foundation is able to raise awareness and support to help change perceptions of the condition and strive for a cure. Support from Jason Colodne and Colbeck Capital are part of a matching opportunity designed to increase donations and inspire others to help drive research, expand knowledge, and advance care for the NF community.
Founded in 1978, the Children's Tumor Foundation is the drug discovery engine for NF. CTF brings treatments to patients faster by connecting doctors, scientists, pharmaceutical partners, and affected families with a mission to end NF. Through a patient-first, collaborative approach, CTF accelerates drug development and delivers life-changing therapies to individuals living with neurofibromatosis and schwannomatosis. To learn more about the foundation, please click here.
About Colbeck Capital Management
Colbeck Capital Management (colbeck.com) is a leading, middle-market private credit manager focused on strategic lending. Colbeck originates senior secured loans to companies going through periods of transition, providing creative capital solutions. Colbeck sponsors its portfolio companies through consistent engagement with management teams in areas such as finance, capital markets and growth strategies, distinguishing itself from traditional lenders. Colbeck was founded in 2009 by Jason Colodne and Jason Beckman and currently manages $3+ billion of invested and committed capital. Colbeck's principals have extensive experience investing through different market cycles at leading institutions, including Goldman Sachs and Morgan Stanley.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Colorcon opens new film coating manufacturing facility in Malaysia
Colorcon has inaugurated a new manufacturing facility in Johor, Malaysia, aimed at enhancing its production capabilities for film coatings. Colorcon provides film coating systems, speciality excipients, controlled release formulations, and controlled atmosphere packaging for the pharmaceutical and nutraceutical industries. The facility, which spans 200,000ft², will create 30 jobs and serve as a key production centre for the Asia-Pacific market. The plant features advanced technology and energy-efficient systems, aligning with Colorcon's commitment to quality in the aforementioned sectors. Colorcon CEO Simon Tasker said: 'We are thrilled to open this world-class facility to support our pharmaceutical customers throughout Asia. 'This investment is aligned with our long-term vision to strengthen and de-risk our supply model for film coatings worldwide. Our goal is to anticipate market growth, adding capacity to ensure we are always a step ahead of demand.' The new facility marks Colorcon's seventh manufacturing site globally, further expanding its operational footprint. Colorcon managing director Willem Hoogwater said: 'We're proud to offer superior film coating technology and a world-class facility to this rapidly growing region. 'Malaysia has quickly become an important hub for high-value pharmaceutical manufacturing, and we're proud to support the local economy with an investment like this.' Colorcon, established in 1961, launched Opadry in 1980, which is claimed to be the first complete film coating system that improved batch uniformity and minimised errors in tablet coating. Since then, Opadry has evolved into a variety of high-performance film coatings that meet different formulation and manufacturing requirements, such as taste-masking, moisture protection, and regulatory compliance. In May this year, Colorcon entered into an exclusive distribution agreement with ASHA Cellulose to supply polymer-based products in select international regions, including Europe, the Middle East, Africa, and Northeast and Southeast Asia. "Colorcon opens new film coating manufacturing facility in Malaysia" was originally created and published by Packaging Gateway, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
5 hours ago
- Yahoo
UBS Bullish on Merck (MRK) Following Verona Pharma Purchase
Merck & Co., Inc. (NYSE:MRK) ranks among the . On July 10, UBS reiterated its Buy rating and $105 price target for Merck & Co., Inc. (NYSE:MRK). Analyst Trung Huynh remained optimistic about the pharmaceutical giant after Merck confirmed that it would acquire London-based Verona Pharma for $10 billion. Pixabay/Public Domain According to consensus estimates of $3.7 billion, the acquisition represents about 2.7 times peak sales, which is consistent with industry norms, according to UBS. The firm believes that Ohtuvayre's launch should benefit from Merck's size and business acumen, much like recent deals like Acceleron. In a call, Merck & Co., Inc. (NYSE:MRK) stated it remains open to $1 billion to $15 billion in additional acquisitions, which UBS believes will be needed to counteract the 2028 Keytruda patent cliff. Merck & Co., Inc. (NYSE:MRK) is a well-known American multinational pharmaceutical firm. Internationally recognized as Merck Sharp & Dohme (MSD), the company is a global provider of prescription medications, vaccines, biologic therapies, and animal health products. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
5 hours ago
- Yahoo
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects
Incyte Corporation (NASDAQ:INCY) is one of the best biotech stocks to buy according to billionaire Steve Cohen. On July 15, UBS reiterated a 'Neutral' rating on the stock and increased its price target to $62 from $61. A pharmacist preparing a dose of an immuno-oncology agent for research use. The price hike comes as UBS expects higher sales for Incyte's Niktimvo, a treatment for chronic Graft-versus-Host Disease (cGVHD). Amid the expected higher sales, UBS has revised its 2026 earnings per share estimate of $6.36 from $6.26. UBS also maintained a 9.5x price-to-earnings multiple on Incyte, as it expects the company's second-quarter earnings call to provide clarity on the company's strategic direction. The company's pipeline has already received a boost following the FDA's extension of the review for ruxolitinib cream for pediatric atopic dermatitis. Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapies in oncology and inflammation & autoimmunity. It also boasts a growing portfolio of treatments for other diseases, including those in dermatology. While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Goldman Sachs REIT Stocks: Top 12 Stock Picks. Disclosure: None. This article is originally published at Insider Monkey.
